What should I ask a patient on Wegovy (semaglutide) during a follow‑up visit?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Wegovy Follow-Up Visit: Essential Assessment Points

At every Wegovy follow-up visit, you must systematically assess weight response, gastrointestinal tolerability, adherence to lifestyle modifications, and screen for serious adverse effects including thyroid symptoms, pancreatitis, gallbladder disease, and mental health changes 1.

Weight and Metabolic Response

Document current weight and calculate percent change from baseline. Wegovy produces mean weight loss of 14.9-16.9% at 68 weeks when combined with lifestyle modifications 2, 3. Ask specifically:

  • Current weight and trajectory over past month
  • Whether weight loss has plateaued or reversed
  • Adherence to reduced-calorie diet (ask about specific dietary changes made)
  • Physical activity level (target 150-200 minutes weekly per STEP protocols) 2

Critical pitfall: Weight regain occurs rapidly after discontinuation—patients regained 11.6% of lost weight within 52 weeks of stopping 2. Emphasize that this is lifelong therapy.

Gastrointestinal Tolerability

Ask directly about nausea, vomiting, diarrhea, constipation, and abdominal pain—these are the most common adverse effects 1, 4. Assess:

  • Severity and frequency of GI symptoms
  • Whether symptoms are improving with continued use (typically transient)
  • Adequacy of oral fluid intake
  • Signs of dehydration (decreased urination, dizziness, dry mouth)

If severe or persistent GI symptoms are present, consider dose reduction or temporary hold 1. The FDA label specifically instructs patients to contact providers for severe/persistent GI symptoms 1.

Serious Adverse Effect Screening

Pancreatitis

Ask about severe abdominal pain radiating to the back, with or without vomiting 1. If suspected, discontinue immediately and obtain lipase/imaging.

Gallbladder Disease

Ask about right upper quadrant pain, especially after meals 1. Rapid weight loss increases cholelithiasis risk even without the medication 1.

Thyroid Symptoms

Ask about neck lumps, hoarseness, difficulty swallowing, or shortness of breath 1. While medullary thyroid carcinoma occurred in rodent studies, human relevance is unknown, but screening is mandated by FDA boxed warning.

Mental Health

Directly ask about depression, suicidal thoughts, or unusual mood changes 1. Instruct patients to stop Wegovy immediately if suicidal ideation emerges.

Cardiovascular and Metabolic Benefits

For patients with established cardiovascular disease, ask about cardiac symptoms including palpitations or racing heartbeat at rest 1. Wegovy reduces major adverse cardiovascular events by 20% in the SELECT trial 3, so document any CV symptoms or events.

If patient has type 2 diabetes:

  • Ask about hypoglycemia symptoms (shakiness, sweating, confusion) 1
  • Ask about vision changes (diabetic retinopathy can worsen with rapid glycemic improvement) 1
  • Consider reducing doses of insulin or sulfonylureas proactively

Medication Adherence and Administration

Verify correct injection technique and timing:

  • Once weekly subcutaneous injection
  • Same day each week preferred
  • Rotation of injection sites (abdomen, thigh, upper arm)

Ask about missed doses—adherence is critical as discontinuation leads to rapid weight regain 2.

Planned Procedures

Ask about any upcoming surgeries or procedures requiring anesthesia 1. Wegovy delays gastric emptying, increasing aspiration risk during general anesthesia or deep sedation. Patients must inform anesthesiologists they are taking this medication.

Pregnancy Status

Ask about pregnancy plans or current pregnancy status in women of childbearing potential 1. Wegovy may cause fetal harm and should be discontinued if pregnancy occurs. Direct patients to pregnancy registry at 1-877-390-2760.

Concomitant Medications

Review for weight-promoting medications that may counteract Wegovy's effects: antidepressants (amitriptyline, mirtazapine), antipsychotics (olanzapine, quetiapine), antiepileptics (gabapentin, carbamazepine), β-blockers, progesterone contraceptives, corticosteroids 2.

Dose Titration Status

Confirm current dose and whether titration schedule is appropriate:

  • Starting dose: 0.25 mg weekly
  • Titrate monthly: 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance)
  • Slower titration may be needed if GI symptoms are limiting 3, 5

Common pitfall: Rushing titration increases GI adverse events and discontinuation rates. The 4-week intervals are evidence-based 5.

References

3
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

What instructions should I give my patients when initiating Ozempic (semaglutide) therapy?
For a 61-year-old patient who has not had laboratory testing in over a year and is requesting weight‑loss medication such as Wegovy (semaglutide), what baseline labs and assessments are required before initiating therapy?
How should Ozempic (semaglutide) be initiated and titrated, what are its contraindications, and what monitoring is required?
How and why should oral semaglutide (Ozempic) be titrated?
What are the side effects and monitoring parameters to consider during Wegovy (semaglutide) treatment for weight loss?
How should I restart lithium therapy for a patient who was previously taking 200 mg and 400 mg doses?
What alternative treatments can be used for herpes in a patient allergic to valacyclovir (Valtrex)?
What does it mean when a laboratory report indicates that hemoglobin is 'hit'?
How should I manage elevated alkaline phosphatase and alanine aminotransferase in a patient with an intra‑abdominal infection?
Can you interpret the shoulder imaging for a 57‑year‑old patient with a two‑ to three‑week history of sharp anterior right‑shoulder pain aggravated by overhead motion, a remote shoulder injury 15 years ago, currently taking ibuprofen 800 mg twice daily, and planning an overseas trip within 30 days?
In a patient with rhabdomyolysis after a fall, acute kidney injury, and pneumonia who is receiving amoxicillin‑clavulanate, gentle intravenous fluids, and now has worsening delirium after switching to intravenous broad‑spectrum antibiotics with urine cultures sent, what additional management steps should be taken?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.